Why pharmaceutical wastewater is a different MBR duty
Pharma effluent is not a generic industrial case. It carries active pharmaceutical ingredients (APIs) from multiple therapeutic classes — antibiotics, antimycotics, cytostatics, anti-inflammatories, iodinated X-ray contrast media — alongside solvents, cleaning-in-place (CIP) chemicals, and variable pH/temperature swings between batches. The Membrane Solutions blog positions flat sheet MBR as the choice for "industrial wastewater…containing large amounts of suspended solids, oils, and chemicals" and names chemical resistance as a primary selection driver.
A pilot MBR installed at a Swiss hospital and operated for one year quantified 68 target analytes simultaneously, spanning 56 pharmaceuticals plus pesticides and endocrine modulators, in a matrix ranging from low ng/L to low mg/L (Janner et al., Environmental Science & Technology, DOI 10.1021/es203495d). Antibiotic residues apply a continuous selection pressure for antimicrobial resistance genes in the bioreactor, which means biomass retention and the downstream disinfection/barrier chain have to be designed with that risk in mind, not just BOD and TSS. Persistent APIs such as carbamazepine pass through both MBR and CAS largely untransformed (Joss et al., Anal Bioanal Chem, 2006), so a flat sheet MBR alone never closes a pharma discharge permit. Because pharma plants are typically space-constrained and the effluent varies batch-to-batch, the modular replaceability of flat sheet MBR elements — for example, the individually replaceable membrane elements in the HydropureWater DF Series flat sheet MBR module — is a practical advantage over hollow fibre for both greenfield and retrofit projects.
What a flat sheet MBR membrane actually does
A flat sheet MBR membrane is a micro-porous filtration plate, immersed in the biological reactor, that physically separates activated sludge and microorganisms from the clarified effluent by negative-pressure suction. The membrane sheet is bonded to a rigid support plate and operates submerged, so there is no pressurized recirculation loop. According to the Membrane Solutions blog, the standard sheet is reinforced PVDF or PES on a support plate, with a typical pore size of 0.1 µm or smaller, which removes suspended solids, bacteria, and most viruses in a single stage. The reference unit characterised in the Joss et al. 2006 study used Kubota A4-size sheets, 0.4 µm pore size, 0.106 m² per sheet, two sheets per module, installed in a 21 L reactor running in parallel with a full-scale CAS line at a municipal WWTP in Rubí, Barcelona. The flat geometry reduces fouling and scaling compared with hollow fibre and is easier to clean in place, which is the main reason pharma and other fouling-prone industrial sites adopt it (Membrane Solutions blog). A modern commercial unit — the HydropureWater DF Series flat sheet MBR module — uses 0.1 µm PVDF, an integrated aeration box for continuous membrane scouring, a stainless steel frame, and individually replaceable elements. The product catalog states that this configuration consumes 10–20× less energy than external cross-flow MBR systems, which is consistent with the negative-pressure-suction principle described in the Membrane Solutions blog.
Pharmaceutical removal performance: what the flat sheet MBR actually does to APIs
The most cited flat-sheet-specific pharmaceutical removal dataset remains the Joss et al. (2006) study of a submerged Kubota 0.4 µm MBR operated in parallel with a CAS line. TSS removal was 98.7% and total COD removal was 90.4% across the membrane process. The same study reported API-by-API removals on real wastewater, summarised below.
| API | Therapeutic class | MBR removal | CAS removal (same study) |
|---|---|---|---|
| Ketoprofen | Anti-inflammatory | >90% | Not consistently >80% |
| Diclofenac | Anti-inflammatory | 87% (avg); >90% in most samples | ~50% |
| Bezafibrate | Lipid regulator | >90% | Variable |
| Gemfibrozil | Lipid regulator | >90% | Variable |
| Ranitidine | Anti-ulcer | >80% | Variable |
| Ofloxacin | Antibiotic (fluoroquinolone) | >80% | Variable |
| Clofibric acid | Lipid regulator metabolite | 65–90% (with two anomalous low-removal events) | Variable |
| Mefenamic acid | Anti-inflammatory | 65–90% (with two anomalous low-removal events) | Variable |
| Propyphenazone | Analgesic | 44.8–82.9% | 6.82–62.6% |
| Glibenclamide | Anti-diabetic | 14.8–73.7% | 11.9–79.7% |
| Carbamazepine | Antiepileptic | <20%; effluent frequently > influent | Also persistent |
Three engineering points follow directly from the Joss et al. 2006 dataset. First, the MBR is materially better than CAS for the most-debated anti-inflammatory API: diclofenac averaged 87% removal in MBR vs. ~50% in the parallel CAS line. Second, the flat sheet MBR reliably hits >80% removal for a wide API set, but two molecules — carbamazepine and, to a lesser extent, glibenclamide — are the boundary cases. The authors explicitly conclude that the MBR process "would not completely halt discharge of micropollutants." Third, on bulk water quality the Membrane Solutions system datasheet reports turbidity <1.0 NTU, SS <1.0 mg/L, and TOC <10 mg/L on a generic 200–400 mg/L COD influent, which is the envelope pharma plants usually require before discharge or RO polishing.
Design parameters for a flat sheet MBR on pharmaceutical duty
The Joss et al. 2006 paper and the HydropureWater product catalog together define the parameter envelope a process engineer should hand to a vendor and use to score an incoming proposal. The list below is parameter-by-parameter; the buyer should still request vendor-specific values for the items where the research is qualitative.
| Parameter | Value or guidance | Source |
|---|---|---|
| Pore size | 0.1 µm PVDF or modified PTFE is the 2026 norm; the Joss 2006 study used 0.4 µm Kubota sheets | Joss et al. 2006; Membrane Solutions; HydropureWater DF Series |
| Membrane material | PVDF (anti-fouling, chemically robust) or modified PTFE (high flux, longer life under heavy solvent/oxidant exposure); PES is more cost-effective but less chemically robust | Membrane Solutions blog; Membrane Solutions system datasheet |
| Sheet geometry | A4 plate-and-frame (Joss 2006 reference: 0.106 m² per sheet); modern skids integrate many sheets per cassette | Joss et al. 2006 |
| Mixed-liquor suspended solids | Up to ~20 mg L⁻¹ achievable in MBR because settleability no longer limits the reactor | Joss et al. 2006 |
| Operating mode | Intermittent permeation: 8 min on / 2 min off (relaxation), as established in the Joss 2006 study | Joss et al. 2006 |
| Aeration | Continuous coarse-bubble scour under the sheets; the HydropureWater integrated MBR system integrates an aeration box for this duty | HydropureWater DF Series catalog; Membrane Solutions |
| Bulk removal | 98.7% TSS, 90.4% total COD on the Joss 2006 reference unit; turbidity <1.0 NTU, SS <1.0 mg/L, TOC <10 mg/L on a 200–400 mg/L COD feed (Membrane Solutions) | Joss et al. 2006; Membrane Solutions |
| Footprint | Integrated MBR systems are documented to occupy roughly 60% less floor area than conventional biology | HydropureWater integrated MBR system catalog |
| Sustainable flux (LMH) at 25 °C | Not stated in the supplied research; request vendor-specific value at design flux and design temperature | Buyer input required |
Three points deserve emphasis. First, the 0.1 µm PVDF norm is tighter than the 0.4 µm Kubota sheets used in Joss 2006, so the modern envelope should be at least as good on turbidity and colloid control, with the trade-off being higher fouling rate per unit permeate. Second, MLSS up to 20 mg L⁻¹ is what enables the high removal of diclofenac, ketoprofen and similar APIs — the reactor is biomass-rich, not membrane-rich, and the API co-metabolism is what does most of the work. Third, sustainable flux is the single number vendors tend to vary the most on, so do not accept a generic LMH figure without a duty-specific curve.
Material, pore size and cleaning: how flat sheet MBR stays alive in a pharma plant
Material selection governs both fouling rate and chemical-cleaning envelope, which directly determines how the membrane survives a pharma CIP regime. The Membrane Solutions blog is explicit: PVDF offers stronger anti-fouling performance, while PES provides higher cost-effectiveness. The choice is therefore governed by the CIP chemical list — if the plant uses oxidative CIP (e.g., peracetic acid, sodium hypochlorite) or aggressive solvent rinses between products, PVDF or modified PTFE is the safer call. The Membrane Solutions flat sheet MBR system datasheet positions modified PTFE flat sheet for "high flux, longer service life, high recovery rate" where solvent and oxidant exposure is heavier. Cleaning method is the second decision: a membrane that supports online backwashing and chemical cleaning is the only realistic configuration in pharma, where taking a skid offline between batches is rarely possible (Membrane Solutions blog). The third decision is replaceability. The HydropureWater DF Series datasheet specifies "individually replaceable membrane elements" and a stainless steel frame, and the engineer should put element-level — not skid-level — replaceability in the RFQ. Element-level replaceability is the single largest OPEX risk mitigator on multi-year pharma projects, because it converts a full membrane replacement into a small parts-and-labour job. Buyers comparing flat sheet MBR modules should review the broader RO/UF membrane filter element range to verify the same vendor offers spare elements with a defined lead time.
Supplier selection framework for a 2026 pharma MBR project
The technical story translates into a five-point supplier scorecard. Use the table below to record incoming bids side by side.
| Criterion | What to ask the vendor | Pass/fail evidence in the research |
|---|---|---|
| Pharma / API reference plants | List of installed MBR systems in API, antibiotic or hospital effluent duty at comparable scale; ask for reference contacts | Joss 2006 (municipal), Janner et al. (hospital pilot) are academic; commercial pharma references must come from the vendor |
| Pore size and material declaration | 0.1 µm PVDF or modified PTFE on the datasheet; full material declaration covering the plant CIP chemical list | HydropureWater DF Series: 0.1 µm PVDF; Membrane Solutions: modified PTFE flat sheet; 0.1 µm is the 2026 norm |
| Energy at design duty | kWh/m³ at design flux and temperature, not a multiplier | HydropureWater DF Series catalog: 10–20× lower energy than external cross-flow MBR systems (qualitative) |
| Modular replaceability and spares | Element-level replaceability, spare stock location, lead time in weeks | HydropureWater DF Series: individually replaceable elements; skids cover 80–225 m² delivering 32–135 m³/day |
| Hydraulic configuration | Submerged, negative-pressure-suction design; reject pressurized flat sheet as non-standard for pharma | Membrane Solutions blog: negative pressure suction, not pressurized filtration, is the standard |
Two practical filters. First, if a vendor cannot produce a kWh/m³ figure at design flux, the energy claim is marketing, not engineering — push back. Second, if the datasheet cannot confirm submerged negative-pressure-suction operation with an integrated aeration box, walk away: pressurized flat sheet is not the pharma configuration. The HydropureWater DF Series flat sheet MBR module is one example of a configuration that meets these checks, but the framework applies to any vendor on the shortlist.
Total cost picture and downstream polishing
A flat sheet MBR is one step in a treatment train, not a standalone discharge solution for pharma. The Joss et al. 2006 result that carbamazepine passes through "largely untransformed" (<20% removal, with effluent sometimes higher than influent) and the authors' explicit statement that the MBR process "would not completely halt discharge of micropollutants" means the train almost always needs a downstream RO, EDI, or advanced oxidation step to meet a regulated effluent API limit. Typical polish trains pair the MBR effluent — turbidity <1 NTU, SS <1 mg/L on a generic 200–400 mg/L COD feed per the Membrane Solutions system datasheet — with an industrial RO system and, where reuse-grade water is required, an EDI Electrodeionization system downstream. The engineer should obtain vendor confirmation that the MBR effluent meets the downstream RO feed SDI requirement before locking the train. The supplied research does not contain pharma-specific CAPEX or OPEX numbers, so the engineer should request four specific line items from each vendor: (a) module CAPEX per m² of installed membrane area, (b) annual CIP chemical consumption in kg or L per m³ treated, (c) guaranteed membrane life in years under the plant's CIP regime, and (d) kWh/m³ at design flux. Without these four numbers the OPEX comparison between vendors is not defensible. A broader RO for wastewater reuse reference and the related MBR membrane bioreactor for pharmaceutical wastewater and MBR membrane module design criteria engineering guides are useful adjuncts when sizing the polish train.
Frequently Asked Questions
Is flat sheet MBR enough on its own for a pharma discharge permit?
No. The Joss et al. 2006 study measured <20% removal for carbamazepine in the flat sheet MBR, with effluent concentrations frequently higher than influent, and concluded that the MBR process "would not completely halt discharge of micropollutants." A downstream RO, activated carbon, or advanced oxidation step is required to close a regulated pharma discharge permit.
What CAPEX and OPEX numbers should I request from a flat sheet MBR vendor for a pharma project?
The supplied research does not contain pharma-specific CAPEX or OPEX figures, so the buyer should request four specific items: module CAPEX per m² of installed membrane area, annual CIP chemical consumption per m³ treated, guaranteed membrane life in years under the plant's CIP regime, and kWh/m³ at design flux. The HydropureWater DF Series covers 80–225 m² per skid delivering 32–135 m³/day, which sets the size envelope to size the request against.
How do I evaluate a flat sheet MBR supplier for a 2026 pharma project?
Score each vendor on five items: pharma or API-sector reference plants of similar scale, pore size and material declaration against the plant's CIP chemical list, kWh/m³ at design duty (not a multiplier), element-level replaceability with stocked spares and a defined lead time, and confirmation of submerged negative-pressure-suction design with an integrated aeration box. Pressurized flat sheet configurations are not standard for pharma and should be rejected.
PVDF vs PES vs PTFE — which membrane material is correct for pharma effluent?
PVDF is the default for anti-fouling performance and chemical resistance (Membrane Solutions blog). PES is more cost-effective but less chemically robust and is only suitable for milder CIP regimes. Modified PTFE is the choice where solvent and oxidant exposure is heavier, because Membrane Solutions positions it for "high flux, longer service life, high recovery rate" under those conditions. Match the material to the plant's full CIP chemical list, not to the bulk effluent alone.
